ATM and cancer: An illustrative example is the use of synthetic lethality‐based approaches to exploit weaknesses in DNA repair pathways with PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) in cancers harboring BRCA or ATM mutations [384].